A meta-analysis was performed to assess the association between the PAI-1 -675 4G/5G polymorphism and susceptibility to diabetes mellitus (DM), diabetic nephropathy (DN), diabetic retinopathy (DR) and diabetic coronary artery disease (CAD). A literature-based search was conducted to identify all relevant studies. The fixed or random effect pooled measure was calculated mainly at the allele level to determine heterogeneity bias among studies. Further stratified analyses and sensitivity analyses were also performed. Publication bias was examined by the modified Begg’s and Egger’s test. Twenty published articles with twenty-seven outcomes were included in the meta-analysis: 6 studies with a total of 1,333 cases and 3,011 controls were analyzed for the PAI-1 -675 4G/5G polymorphism with diabetes risk, 7 studies with 1,060 cases and 1,139 controls for DN risk, 10 studies with 1,327 cases and 1,557 controls for DR and 4 studies with 610 cases and 1,042 controls for diabetic CAD risk respectively. Using allelic comparison (4G vs. 5G), the PAI-1 -675 4G/5G polymorphism was observed to have no significant association with diabetes (REM OR 1.07, 95% CI 0.96, 1.20), DN (REM OR 1.10, 95% CI 0.98, 1.25), DR (REM OR 1.09, 95% CI 0.97, 1.22) or diabetic CAD risk (REM OR 1.07, 95% CI 0.81, 1.42), and similar results were obtained in the dominant, recessive and co-dominant models. Our meta-analyses suggest that the PAI-1 -675 4G/5G polymorphism might not be a risk factor for DM, DN, DR or diabetic CAD risk in the populations investigated. This conclusion warrants confirmation by further studies.
References
[1]
Vassalli JD, Sappino AP, Belin D (1991) The plasminogen activator/plasmin system. J Clin Invest 88: 1067-1072. doi:10.1172/JCI115405. PubMed: 1833420.
[2]
Festa A, D'Agostino R Jr, Tracy RP, Haffner SM (2002) Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51: 1131-1137. doi:10.2337/diabetes.51.4.1131. PubMed: 11916936.
[3]
Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM (2006) Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 113: 1753-1759. doi:10.1161/CIRCULATIONAHA.106.616177. PubMed: 16585388.
[4]
Gori AM, Marcucci R, Fatini C, Gensini F, Sticchi E et al. (2004) Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thromb Haemost 92: 54-60. PubMed: 15213845.
[5]
Steinberger J, Daniels SR (2003) Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 107: 1448-1453. doi:10.1161/01.CIR.0000060923.07573.F2. PubMed: 12642369.
[6]
Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L et al. (2005) Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 36: 1661-1665. doi:10.1161/01.STR.0000174485.10277.24. PubMed: 16020771.
[7]
Eriksson P, Kallin B, van 't Hooft FM, B？venholm P, Hamsten A (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 92: 1851-1855. doi:10.1073/pnas.92.6.1851. PubMed: 7892190.
[8]
Mansfield MW, Stickland MH, Grant PJ (1995) Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 74: 842-847. PubMed: 8571308.
[9]
Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC et al. (1997) Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care 20: 1304-1309. doi:10.2337/diacare.20.8.1304. PubMed: 9250459.
[10]
Broch M, Gutierrez C, Aguilar C, Simon I, Richart C et al. (1998) Genetic variation in promoter (4G/5G) of plasminogen activator inhibitor 1 gene in type 2 diabetes. Absence of relationship with microangiopathy. Diabetes Care 21: 463. doi:10.2337/diacare.21.3.463a.
[11]
Kimura H, Gejyo F, Suzuki Y, Suzuki S, Miyazaki R et al. (1998) Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1. Kidney Int 54: 1659-1669. doi:10.1046/j.1523-1755.1998.00139.x. PubMed: 9844142.
[12]
De Cosmo S, Margaglione M, Tassi V, Garrubba M, Thomas S et al. (1999) ACE, PAI-1, decorin and Werner helicase genes are not associated with the development of renal disease in European patients with type 1 diabetes. Diabetes/Metab Res Rev 15: 247-253. doi:10.1002/(SICI)1520-7560(199907/08)15:4.
[13]
Tarnow L, Stehouwer CD, Emeis JJ, Poirier O, Cambien F et al. (2000) Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. Nephrol Dial Transplant 15: 625-630. doi:10.1093/ndt/15.5.625. PubMed: 10809802.
[14]
Wong TY, Poon P, Szeto CC, Chan JC, Li PK (2000) Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int 57: 632-638. doi:10.1046/j.1523-1755.2000.00884.x. PubMed: 10652041.
[15]
Globocnik-Petrovic M, Hawlina M, Peterlin B, Petrovic D (2003) Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes. Ophthalmologica 217: 219-224. doi:10.1159/000068975. PubMed: 12660488.
[16]
Lopes C, Dina C, Durand E, Froguel P (2003) PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia 46: 1284-1290. doi:10.1007/s00125-003-1170-0. PubMed: 12856128.
[17]
Petrovic D, Globocnik-Petrovic M, Peterlin B (2003) 4G4G genotype of PAI-1 gene promoter polymorphism is not associated with myocardial infarction in Caucasians with type-2 diabetes. Cardiology 100: 157-158. doi:10.1159/000073935. PubMed: 14631138.
[18]
Santos KG, Tschiedel B, Schneider J, Souto K, Roisenberg I (2003) Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes. Diabetes Res Clin Pract 61: 133-136. doi:10.1016/S0168-8227(03)00112-8. PubMed: 12951282.
[19]
Liu SQ, Xue YM, Yang GC, He FY, Zhao XS (2004) Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province. Di Yi Jun Yi Xue Xue Bao 24: 904-907.
[20]
Zietz B, Buechler C, Drobnik W, Herfarth H, Sch？lmerich J et al. (2004) Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels. Endocr Res 30: 443-453. doi:10.1081/ERC-200035728. PubMed: 15554360.
[21]
Murata M, Maruyama T, Suzuki Y, Saruta T, Ikeda Y (2004) Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Diabet Med 21: 837-844. doi:10.1111/j.1464-5491.2004.01252.x. PubMed: 15270786.
[22]
Meigs JB, Dupuis J, Liu C, O'Donnell CJ, Fox CS et al. (2006) PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample. Obesity (Silver Spring) 14: 753-758. doi:10.1038/oby.2006.85.
[23]
Martin RJ, Savage DA, Patterson CC, Brady HR, Maxwell AP (2007) Common polymorphisms of the PAI1 gene do not play a major role in the development of diabetic nephropathy in Type 1 diabetes. Diabet Med 24: 259-265. doi:10.1111/j.1464-5491.2007.02087.x. PubMed: 17263760.
[24]
Saely CH, Muendlein A, Vonbank A, Sonderegger G, Aczel S et al. (2008) Type 2 diabetes significantly modulates the cardiovascular risk conferred by the PAI-1 -675 4G/5G polymorphism in angiographied coronary patients. Clin Chim Acta 396: 18-22. doi:10.1016/j.cca.2008.06.015. PubMed: 18619429.
[25]
Ezzidi I, Mtiraoui N, Chaieb M, Kacem M, Mahjoub T et al. (2009) Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients. Diabetes Metab 35: 214-219. doi:10.1016/j.diabet.2008.12.002. PubMed: 19419896.
[26]
Prasad P, Tiwari AK, Kumar KM, Ammini AC, Gupta A et al. (2010) Association analysis of ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes. BMC Med Genet 11: 52. doi:10.1186/1471-2350-11-52. PubMed: 20353610.
[27]
Al-Hamodi Z, Saif-Ali R, Ismail IS, Ahmed KA, Muniandy S (2012) Effect of plasminogen activator inhibitor-1 and tissue plasminogen activator polymorphisms on susceptibility to type 2 diabetes in Malaysian subjects. J Biomed Biotechnol, 2012: 234937. PubMed: 22577291.
[28]
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8: 336-341. doi:10.1016/j.ijsu.2010.02.007. PubMed: 20171303.
[29]
Parmar MKB, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. doi:10.1002/(SICI)1097-0258(19981230)17:24. PubMed: 9921604.
[30]
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. doi:10.1136/bmj.315.7109.629. PubMed: 9310563.
[31]
Naran NH, Chetty N, Crowther NJ (2008) The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity. Atherosclerosis 196(1): 155-163. doi:10.1016/j.atherosclerosis.2007.03.024. PubMed: 17467713.
[32]
Brazionis L, Rowley K, Jenkins A, Itsiopoulos C, O'Dea K (2008) Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy. Arterioscler Thromb Vasc Biol 28: 786-791. doi:10.1161/ATVBAHA.107.160168. PubMed: 18239151.
[33]
Lassila M, Fukami K, Jandeleit-Dahm K, Semple T, Carmeliet P et al. (2007) Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. Diabetologia 50: 1315-1326. doi:10.1007/s00125-007-0652-x. PubMed: 17415547.
[34]
Seo JY, Park J, Yu MR, Kim YS, Ha H et al. (2009) Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes. Am J Nephrol 30: 481-490. doi:10.1159/000242477. PubMed: 19786738.
[35]
Munafò MR, Flint J (2004) Meta-analysis of genetic association studies. Trends Genet 20: 439-444. doi:10.1016/j.tig.2004.06.014. PubMed: 15313553.
[36]
Patsopoulos NA, Evangelou E, Ioannidis JP (2008) Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 37: 1148-1157. doi:10.1093/ije/dyn065. PubMed: 18424475.
[37]
Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG (2003) Genetic associations in large versus small studies: an empirical assessment. Lancet 361: 567-571. doi:10.1016/S0140-6736(03)12516-0. PubMed: 12598142.
